WO2003004529A3 - Ephrin-tie receptor materials and methods - Google Patents

Ephrin-tie receptor materials and methods Download PDF

Info

Publication number
WO2003004529A3
WO2003004529A3 PCT/IB2002/002524 IB0202524W WO03004529A3 WO 2003004529 A3 WO2003004529 A3 WO 2003004529A3 IB 0202524 W IB0202524 W IB 0202524W WO 03004529 A3 WO03004529 A3 WO 03004529A3
Authority
WO
Grant status
Application
Patent type
Prior art keywords
ephrin
methods
tie receptor
receptor materials
materials
Prior art date
Application number
PCT/IB2002/002524
Other languages
French (fr)
Other versions
WO2003004529A2 (en )
Inventor
Kari Alitalo
Hajime Kubo
Original Assignee
Licentia Ltd
Kari Alitalo
Hajime Kubo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators

Abstract

The present invention provides materials and methods relating to the interaction between Tie receptors and Ephrin polypeptides.
PCT/IB2002/002524 2001-07-02 2002-07-02 Ephrin-tie receptor materials and methods WO2003004529A3 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US30296001 true 2001-07-02 2001-07-02
US60/302,960 2001-07-02

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AU2002314433A AU2002314433A1 (en) 2001-07-02 2002-07-02 Ephrin-tie receptor materials and methods

Publications (2)

Publication Number Publication Date
WO2003004529A2 true WO2003004529A2 (en) 2003-01-16
WO2003004529A3 true true WO2003004529A3 (en) 2004-06-10

Family

ID=23169976

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2002/002524 WO2003004529A3 (en) 2001-07-02 2002-07-02 Ephrin-tie receptor materials and methods

Country Status (1)

Country Link
WO (1) WO2003004529A3 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9562049B2 (en) 2012-12-21 2017-02-07 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US9567340B2 (en) 2012-12-21 2017-02-14 Medimmune Limited Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases
US10029018B2 (en) 2013-10-11 2018-07-24 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003040304A3 (en) * 2001-11-09 2004-02-05 Neuronova Ab Method of proliferation in neurogenic regions
GB0208089D0 (en) 2002-04-09 2002-05-22 Oxford Glycosciences Uk Ltd Protein
US7485297B2 (en) 2003-08-12 2009-02-03 Dyax Corp. Method of inhibition of vascular development using an antibody
EP2478912B1 (en) 2003-11-06 2016-08-31 Seattle Genetics, Inc. Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy
KR101270829B1 (en) 2004-09-23 2013-06-07 제넨테크, 인크. Cystein engineered antibodies and conjugates
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
WO2011031870A1 (en) 2009-09-09 2011-03-17 Centrose, Llc Extracellular targeted drug conjugates
ES2544608T3 (en) 2010-11-17 2015-09-02 Genentech, Inc. Conjugates of the antibody and alaninyl-maytansinol
RU2638806C2 (en) 2011-05-12 2017-12-15 Дженентек, Инк. Lc-ms/ms method for multiple reactions monitoring to identify therapeutic antibodies in animal species using framework signature peptides
WO2013130093A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
JP5993093B2 (en) 2012-10-12 2016-09-14 メドイミューン・リミテッドMedImmune Limited Pyrrolo benzodiazepines and their complexes
CN105050661B (en) 2012-10-12 2018-03-30 Adc疗法责任有限公司 Pyrrolo benzodiazepine - antibody conjugate
KR20150085814A (en) 2012-10-12 2015-07-24 에이디씨 테라퓨틱스 에스에이알엘 Pyrrolobenzodiazepine-antibody conjugates
CN105209077A (en) 2013-03-13 2015-12-30 麦迪穆有限责任公司 Pyrrolobenzodiazepines and conjugates thereof
KR20150131203A (en) 2013-03-13 2015-11-24 메디뮨 리미티드 Pyrrolobenzodiazepines and conjugates thereof
WO2015095212A1 (en) 2013-12-16 2015-06-25 Genentech, Inc. 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
CA2918139A1 (en) 2013-08-12 2015-02-19 Genentech, Inc. 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
WO2015052532A1 (en) 2013-10-11 2015-04-16 Spirogen Sàrl Pyrrolobenzodiazepine-antibody conjugates
US9956299B2 (en) 2013-10-11 2018-05-01 Medimmune Limited Pyrrolobenzodiazepine—antibody conjugates
US9950078B2 (en) 2013-10-11 2018-04-24 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
CN107106700A (en) 2013-12-16 2017-08-29 基因泰克公司 Peptidomimetic compounds and antibody-drug conjugates thereof
WO2016037644A1 (en) 2014-09-10 2016-03-17 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
JP2017531620A (en) 2014-09-12 2017-10-26 ジェネンテック, インコーポレイテッド Cysteine ​​engineered antibodies and conjugates
US20160074528A1 (en) 2014-09-12 2016-03-17 Genentech, Inc. Anthracycline disulfide intermediates, antibody-drug conjugates and methods
CA2959689A1 (en) 2014-09-17 2016-03-24 Genentech, Inc. Pyrrolobenzodiazepines and antibody disulfide conjugates thereof
US10058613B2 (en) 2015-10-02 2018-08-28 Genentech, Inc. Pyrrolobenzodiazepine antibody drug conjugates and methods of use
EP3362100A1 (en) 2015-10-16 2018-08-22 Genentech, Inc. Hindered disulfide drug conjugates
WO2017068511A1 (en) 2015-10-20 2017-04-27 Genentech, Inc. Calicheamicin-antibody-drug conjugates and methods of use
CN108700598A (en) 2016-03-25 2018-10-23 豪夫迈·罗氏有限公司 Multiplexing total antibody and conjugated drug antibody assay quantization
WO2017201449A1 (en) 2016-05-20 2017-11-23 Genentech, Inc. Protac antibody conjugates and methods of use
WO2017205741A1 (en) 2016-05-27 2017-11-30 Genentech, Inc. Bioanalytical method for the characterization of site-specific antibody-drug conjugates
US20170348422A1 (en) 2016-06-06 2017-12-07 Genentech, Inc. Silvestrol antibody-drug conjugates and methods of use
WO2018031662A1 (en) 2016-08-11 2018-02-15 Genentech, Inc. Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
WO2018065501A1 (en) 2016-10-05 2018-04-12 F. Hoffmann-La Roche Ag Methods for preparing antibody drug conjugates

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000030673A1 (en) * 1998-11-20 2000-06-02 Genentech, Inc. Uses for eph receptor antagonists and agonists to treat vascular disorders
WO2001012840A2 (en) * 1999-08-17 2001-02-22 Purdue Research Foundation Anti-epha2 antibodies as a cancer diagnostic
WO2001097850A2 (en) * 2000-06-23 2001-12-27 Schering Aktiengesellschaft Combinations and compositions which interfere with vegf/vegf and angiopoietin/tie receptor function and their use (ii)

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000030673A1 (en) * 1998-11-20 2000-06-02 Genentech, Inc. Uses for eph receptor antagonists and agonists to treat vascular disorders
WO2001012840A2 (en) * 1999-08-17 2001-02-22 Purdue Research Foundation Anti-epha2 antibodies as a cancer diagnostic
WO2001097850A2 (en) * 2000-06-23 2001-12-27 Schering Aktiengesellschaft Combinations and compositions which interfere with vegf/vegf and angiopoietin/tie receptor function and their use (ii)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9562049B2 (en) 2012-12-21 2017-02-07 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US9567340B2 (en) 2012-12-21 2017-02-14 Medimmune Limited Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases
US10029018B2 (en) 2013-10-11 2018-07-24 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof

Also Published As

Publication number Publication date Type
WO2003004529A2 (en) 2003-01-16 application

Similar Documents

Publication Publication Date Title
WO2004029207A3 (en) Optimized fc variants and methods for their generation
WO2000001815A3 (en) Neurotrophic factors
WO2004073634A3 (en) Phenylenediamine urotensin-ii receptor antagonists and ccr-9 antagonists
WO2002072826A3 (en) Neurotrophic factors
WO2005077981A3 (en) Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES
GB0111958D0 (en) Waterproofing
GB0218229D0 (en) Antibodies

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP